KTRA

Tuhura Biosciences Inc. (KTRA) | Rumor.io

Tuhura Biosciences

KTRA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,600

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization115.6M

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.3M

Social

What share of all stock conversation is about KTRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 29

Analysts have set a price target for KTRA of $SPY for next week.
New alerts have been posted for KTRA in the last hours.
Analysts have set a price target for KTRA of for today.

Generated by AI

Sentiment

Of the messages about KTRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.16% -3.03
Bearish	—	—	—	9.84% +3.03

Bullish· Jun 23

KTRA is expected to surge upwards, indicated by the use of rocket ship emojis and the phrase "Here we Go".
The asset is likely to generate significant returns, as suggested by the 💸 symbol and the arrow pointing upwards.
The mention of "Here we go" implies a sense of momentum and forward movement, indicating a bullish outlook for KTRA.

Bearish· Oct 31

Kintara Therapeutics' stock has been significantly impacted by the failure of its VAL-083 trial, with shares down 80% and 74% at various points.
The company's VAL-083 trial failed to perform better than current standards of care in glioblastoma, raising concerns about the treatment's effectiveness.
Kintara Therapeutics has been downgraded to a "hold" rating from a "buy" rating at Maxim Group, indicating a reduced outlook for the company's stock.

Generated by AI

Topics

Of the messages about KTRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	72.73%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	27.27%

Announcements· Jul 1

Kintara Therapeutics and TuHURA Biosciences have announced recent corporate and clinical advancements, with near-term milestones outlined.
The companies are working on a 40m dollar merger, with Kintara Therapeutics also partnering with Merck & Co. (MRK), a 317 billion dollar market cap company.
TuHURA Biosciences focuses on cancer immunotherapy, including bifunctional ADCs and a Phase 3 trial for a cancer vaccine, with the merger expected to close in Q3 2024.

Technical Analysis· Nov 28

$KTRA has a descending triangle pattern on the 1-minute chart, with a key support level at $4.70.
The stock is looking for a downtrend reversal breakout, with a potential bottoming turnaround and a short float of 3.5%.
Key technical levels for $KTRA include resistance at $5.10, $5.31, and $5.53, and support at $4.49, $4.31, $4.12, and further below.

Generated by AI

Community

Of the messages about KTRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	38.27%
Newcomers	100%	100%	100%	61.73%

Regulars· Sep 26

The merger announcement has been approved, and the stock is experiencing a significant surge, up 40% in the morning.
The company has a strong oncology pipeline with a promising cancer vaccine that has shown sustained tumor shrinkage in Merkel-cell carcinoma.
The stockholders need to vote for a reverse split to complete the merger, which is a necessary step for the company's next phase.

Newcomers· Jun 27

Newcomers are identifying a potential Cup and Handle chart pattern in KTRA's daily chart, predicting a breakout and subsequent price increase.
Some users believe that KTRA's merger news will lead to a buying frenzy, with short positions being covered and prices rising.
Others are waiting for KTRA to break through $0.37, which they believe will send the price up, and are expecting a bounce before the company's reverse stock split (R/S) is completed.

Generated by AI

Also Discussed

Investors talking about KTRA also mention

#	Name	Attention
1	Kazia Therapeutics Ltd Sponsored ADRKZIA	0%new
2	BXRX - Baudax Bio, Inc.	——
3	NRBO - NeuroBo Pharmaceuticals, Inc.	——
4	NLS Pharmaceutics LtdNLSP	0%0
5	CNXA - Connexa Sports Technologies Inc.	——
6	PEGY - Pineapple Energy Inc.	——
7	BRSH - Bruush Oral Care Inc.	——
8	SLNA - Selina Hospitality PLC	——
9	Crown Electrokinetics Corp.CRKN	0%0
10	Presurance Holdings, Inc.CNFR	0%0

Tuhura Biosciences Inc.

Healthcare
Biotechnology

Tuhura Biosciences Inc. is a biotechnology company involved in discovering and developing innovative therapies to address unmet medical needs. The company's primary function is to enhance the quality of life for patients by focusing on cutting-edge research and leveraging advanced technologies in drug discovery and development. Tuhura Biosciences operates at the intersection of healthcare and technology, influencing the biotechnology and pharmaceutical industries. Its research initiatives are geared towards understanding complex biological systems and translating this knowledge into actionable medical interventions. By harnessing the power of data-driven insights and precision medicine, Tuhura Biosciences plays a significant role in the market, contributing to the advancement of personalized healthcare solutions and offering potential breakthroughs in the treatment landscape for various diseases. Its presence underscores the growing momentum in the biosciences sector, as companies strive to bring new therapies from the laboratory to the clinic, ultimately aiming to improve patient outcomes globally.

Website

Location

9920 Pacific Heights Blvd

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about KTRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 29

Analysts have set a price target for KTRA of $SPY for next week.
New alerts have been posted for KTRA in the last hours.
Analysts have set a price target for KTRA of for today.

Generated by AI

Sentiment

Of the messages about KTRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.16% -3.03
Bearish	—	—	—	9.84% +3.03

Bullish· Jun 23

KTRA is expected to surge upwards, indicated by the use of rocket ship emojis and the phrase "Here we Go".
The asset is likely to generate significant returns, as suggested by the 💸 symbol and the arrow pointing upwards.
The mention of "Here we go" implies a sense of momentum and forward movement, indicating a bullish outlook for KTRA.

Bearish· Oct 31

Kintara Therapeutics' stock has been significantly impacted by the failure of its VAL-083 trial, with shares down 80% and 74% at various points.
The company's VAL-083 trial failed to perform better than current standards of care in glioblastoma, raising concerns about the treatment's effectiveness.
Kintara Therapeutics has been downgraded to a "hold" rating from a "buy" rating at Maxim Group, indicating a reduced outlook for the company's stock.

Generated by AI

Topics

Of the messages about KTRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	72.73%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	27.27%

Announcements· Jul 1

Kintara Therapeutics and TuHURA Biosciences have announced recent corporate and clinical advancements, with near-term milestones outlined.
The companies are working on a 40m dollar merger, with Kintara Therapeutics also partnering with Merck & Co. (MRK), a 317 billion dollar market cap company.
TuHURA Biosciences focuses on cancer immunotherapy, including bifunctional ADCs and a Phase 3 trial for a cancer vaccine, with the merger expected to close in Q3 2024.

Technical Analysis· Nov 28

$KTRA has a descending triangle pattern on the 1-minute chart, with a key support level at $4.70.
The stock is looking for a downtrend reversal breakout, with a potential bottoming turnaround and a short float of 3.5%.
Key technical levels for $KTRA include resistance at $5.10, $5.31, and $5.53, and support at $4.49, $4.31, $4.12, and further below.

Generated by AI

Community

Of the messages about KTRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	38.27%
Newcomers	100%	100%	100%	61.73%

Regulars· Sep 26

The merger announcement has been approved, and the stock is experiencing a significant surge, up 40% in the morning.
The company has a strong oncology pipeline with a promising cancer vaccine that has shown sustained tumor shrinkage in Merkel-cell carcinoma.
The stockholders need to vote for a reverse split to complete the merger, which is a necessary step for the company's next phase.

Newcomers· Jun 27

Newcomers are identifying a potential Cup and Handle chart pattern in KTRA's daily chart, predicting a breakout and subsequent price increase.
Some users believe that KTRA's merger news will lead to a buying frenzy, with short positions being covered and prices rising.
Others are waiting for KTRA to break through $0.37, which they believe will send the price up, and are expecting a bounce before the company's reverse stock split (R/S) is completed.

Generated by AI

Tuhura Biosciences

Social

Jun 29

Sentiment

Bullish· Jun 23

Bearish· Oct 31

Topics

Announcements· Jul 1

Technical Analysis· Nov 28

Community

Regulars· Sep 26

Newcomers· Jun 27

Also Discussed

Tuhura Biosciences Inc.

Company Information

Location

Social

Jun 29

Sentiment

Bullish· Jun 23

Bearish· Oct 31

Topics

Announcements· Jul 1

Technical Analysis· Nov 28

Community

Regulars· Sep 26

Newcomers· Jun 27

Also Discussed